Relapsed small-cell lung cancer has long been one of the most difficult malignancies to treat once platinum-based chemotherapy fails, with...

The 2026 World Medical Innovation Forum showcased experimental precision-frozen pig organs, a preclinical pancreatic-cancer immunotherapy, AI-enabled cardiovascular screening and a...

A collagen-targeted protein MRI contrast agent developed at Georgia State University detected invasive lung tumors and multi-organ metastases as small...

A meta-analysis of six randomized trials found that adding PD-1/PD-L1 inhibitors to chemotherapy was associated with longer progression-free and overall...

A computational and laboratory study found that reducing HLTF diminished prostate cancer cell proliferation and suggested regulation of ZBP1-PANoptosome assembly...

A prespecified interim analysis of the phase 3 HARMONi-2 trial shows ivonescimab achieved median overall survival of 30.8 months versus...

A retrospective cohort of 163 patients treated at one Rwandan cancer center reported estimated median overall survival of 3.68 years...

In the phase 3 REZILIENT 3 trial, adding zipalertinib to platinum-pemetrexed chemotherapy extended median progression-free survival from 8.5 to 14.5...

A retrospective study of 430 surgically treated patients links elevated inflammation, thyroid-related blood markers and selected immune-cell measures with survival...

A new study shows that VEGF-driven retinal neovascularization depends on a VEGFR2-VEGFR3-ATF6-GRP78 signaling axis that induces the chemokines CXCL1/2 and...